Cerebral Blood Flow and Ventilatory Responses During Sleep in Normoxia and Intermittent Hypoxia
NCT ID: NCT03255408
Last Updated: 2022-11-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
12 participants
INTERVENTIONAL
2023-01-01
2024-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Determinants of Age Related Breathing Instability During Non-Rapid-Eye-Movement (NREM) Sleep
NCT00732199
Neuropsychological Sleep Physical Exercise Hypoxia
NCT01386814
The Impact of Arousal Threshold in Obstructive Sleep Apnea
NCT02264353
Feasibility of Improving Sleep Apnea Treatment Adherence After Brain Injury
NCT04221009
Autonomic Activity During Nap Under Hypoxia
NCT04146857
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A pharmacological intervention will be utilized to manipulate the CBF in a randomized order. The study participants will also be randomly assigned the order to sleep either under normoxia or IH exposure. The experiments will be separated from one another with an interval of sufficient drug and IH exposure washout period. The venous blood samples and urinary samples will be collected for the vascular biomarkers.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CBF Lowering and Normoxia Sleep
Study participants will take drug lowering Cerebral Blood Flow (CBF) and sleep under room air i.e. normoxia exposure.
Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep
The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Normoxia Exposure
CBF Lowering and IH Sleep
Study participants will take drug lowering Cerebral Blood Flow (CBF) and sleep under Intermittent Hypoxia (IH) exposure.
Drug Lowering CBF and Intermittent Hypoxia Sleep
The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Intermittent Hypoxia (IH) Exposure
Placebo and Normoxia Sleep
Study participants will take Placebo that has no effect on Cerebral Blood Flow (CBF) and sleep under room air i.e. normoxia exposure.
Placebo and Normoxia Sleep
The study participants will take Placebo and sleep under Normoxia Exposure
Placebo and IH Sleep
Study participants will take Placebo that has no effect on Cerebral Blood Flow (CBF) and sleep under Intermittent Hypoxia (IH) exposure.
Placebo and Intermittent Hypoxia Sleep
The study participants will take Placebo and sleep under Intermittent Hypoxia (IH) Exposure
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep
The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Normoxia Exposure
Drug Lowering CBF and Intermittent Hypoxia Sleep
The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Intermittent Hypoxia (IH) Exposure
Placebo and Normoxia Sleep
The study participants will take Placebo and sleep under Normoxia Exposure
Placebo and Intermittent Hypoxia Sleep
The study participants will take Placebo and sleep under Intermittent Hypoxia (IH) Exposure
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 - 45 years of age
* Living in Calgary for the past one year
* Have no medical condition or should not be taking any blood pressure medications.
* The participant should not be lactose intolerant
Exclusion Criteria
* Bleeding disorders and upper gastrointestinal diseases e.g. peptic ulcer disease
* Pregnancy, obese and sleep-disordered breathing
* Drug allergies to non-steroidal anti-inflammatories
* Currently smoking
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Calgary
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marc Poulin
PhD, DPhil, Professor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REB13-0880
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.